Abstract

Sir2 (silent information regulator 2) enzymes catalyze a unique protein deacetylation reaction that requires the coenzyme NAD(+) and produces nicotinamide and a newly discovered metabolite, O-acetyl-ADP-ribose (OAADPr). Conserved from bacteria to humans, these proteins are implicated in the control of gene silencing, metabolism, apoptosis, and aging. Here we examine the role of NAD(+) metabolites/derivatives and salvage pathway intermediates as activators, inhibitors, or coenzyme substrates of Sir2 enzymes in vitro. Also, we probe the coenzyme binding site using inhibitor binding studies and alternative coenzyme derivatives as substrates. Sir2 enzymes showed an exquisite selectivity for the nicotinamide base coenzyme, with the most dramatic losses in binding affinity/reactivity resulting from relatively minor changes in the nicotinamide ring, either by reduction, as in NADH, or by converting the amide to its acid analogue. Both ends of the dinucleotide NAD(+) are shown to be critical for high selectivity and high affinity. Among the NAD(+) metabolites tested none were able to allosterically activate, although all led to various extents of inhibition, consistent with competition at the coenzyme binding site. Nicotinamide was the most potent inhibitor examined, suggesting that cellular nicotinamide levels would provide an effective small molecule regulator of protein deacetylation and generation of OAADPr. The presented findings also suggest that changes in the physiological NAD(+):NADH ratio, without a change in NAD(+), would yield little alteration in Sir2 activity. That is, NADH is an extremely ineffective inhibitor of Sir2 enzymes (average IC(50) of 17 mm). We propose that changes in both free nicotinamide and free NAD(+) afford the greatest contribution to cellular activity of Sir2 enzymes but with nicotinamide having a more dramatic effect during smaller fluctuations in concentration.

Highlights

  • Sir2 enzymes catalyze a unique protein deacetylation reaction that requires the coenzyme NAD؉ and produces nicotinamide and a newly discovered metabolite, O-acetyl-ADP-ribose (OAADPr)

  • The yeast Sir2 homolog HST2 was used as the primary test case; ySir2 and human

  • Given the poor inhibition of HST2 by NADH, and its proposed role in directly regulating ySir2, we examined NADH inhibition with ySir2 as well as human SIRT2 under identical assay conditions

Read more

Summary

Introduction

Sir (silent information regulator 2) enzymes catalyze a unique protein deacetylation reaction that requires the coenzyme NAD؉ and produces nicotinamide and a newly discovered metabolite, O-acetyl-ADP-ribose (OAADPr). We examine the role of NAD؉ metabolites/derivatives and salvage pathway intermediates as activators, inhibitors, or coenzyme substrates of Sir enzymes in vitro. Sir enzymes showed an exquisite selectivity for the nicotinamide base coenzyme, with the most dramatic losses in binding affinity/reactivity resulting from relatively minor changes in the nicotinamide ring, either by reduction, as in NADH, or by converting the amide to its acid analogue. Both ends of the dinucleotide NAD؉ are shown to be critical for high selectivity and high affinity. Anderson et al [24] have demonstrated that increased dosage of several salvage pathway genes in yeast results in increased gene silencing nicotinamide adenine dinucleotide; OAADPr, O-acetyl-ADP-ribose; NMNϩ, nicotinamide mononucleotide; NAMNϩ, nicotinic acid mononucleotide; NAADϩ, nicotinic acid adenine dinucleotide; NADPϩ, nicotinamide adenine dinucleotide phosphate; thio-NADϩ, thionicotinamide adenine dinucleotide; 3-AcPAD, 3-acetylpyridine adenine dinucleotide; 3-hPADϩ, 3-hydroxypyridine adenine dinucleotide; NGDϩ, nicotinamide guanine dinucleotide; NHDϩ, nicotinamide hypoxanthine dinucleotide; AcH3, acetylated H3 peptide; DTT, dithiothreitol

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call